Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage);  ; cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage) - capsule - 250 mg - active: cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage)   excipient: brilliant blue fcf carmoisine colloidal silicon dioxide croscarmellose sodium gelatin   magnesium stearate methyl hydroxybenzoate   ponceau 4r pregelatinised maize starch propyl hydroxybenzoate   titanium dioxide   water   active: cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage) excipient: brilliant blue fcf carmoisine colloidal silicon dioxide croscarmellose sodium gelatin   magnesium stearate methyl hydroxybenzoate   ponceau 4r pregelatinised maize starch propyl hydroxybenzoate   titanium dioxide   - · lower respiratory infections, including pneumonia caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains), and s. pyogenes (group a beta- haemolytic streptococci), m.catarrhalis, acute bronchitis, and acute exacerbations of chronic bronchitis. · upper respiratory infections, including pharyngitis and tonsillitis caused by s. pyogenes (group a beta-haemolytic streptococci) and m. catarrhalis. note: penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. amoxicillin has been recommended by the american heart association as the standard regimen for the prophylaxis of bacterial endocarditis for dental, oral, and upper respiratory tract procedures, with penicillin v a rational and acceptable alternative in the prophylaxis against beta-haemolytic streptococcal bacteriaemia in this setting. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever or bacterial endocarditis are not available at present.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 535mg equivalent to cefaclor 500 mg (plus 2% overage.) - capsule - 500 mg - active: cefaclor monohydrate 535mg equivalent to cefaclor 500 mg (plus 2% overage.) excipient: brilliant blue fcf carmoisine colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide black magnesium stearate methyl hydroxybenzoate   ponceau 4r pregelatinised maize starch propyl hydroxybenzoate   titanium dioxide  

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 405.27mg equivalent to cefaclor 375 mg - modified release tablet - 375 mg - active: cefaclor monohydrate 405.27mg equivalent to cefaclor 375 mg excipient: colloidal silicon dioxide hyprolose hypromellose lactose monohydrate magnesium stearate opacode opadry blue purified talc

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 27.8 mg/ml equivalent to cefaclor 25 mg/ml;   - granules for oral suspension - 125 mg/5ml - active: cefaclor monohydrate 27.8 mg/ml equivalent to cefaclor 25 mg/ml   excipient: allura red ac citric acid colloidal silicon dioxide simeticone sodium benzoate sodium citrate dihydrate strawberry flavour 052311 ap0551 sucrose xanthan gum - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: lower respiratory infections, including pneumonia caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains), and s. pyogenes (group a beta- haemolytic streptococci), m.catarrhalis, acute bronchitis, and acute exacerbations of chronic bronchitis. upper respiratory infections, including pharyngitis and tonsillitis caused by s. pyogenes (group a beta-haemolytic streptococci) and m. catarrhalis. otitis media caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains) staphylococci, and s. pyogenes (group a beta-haemolytic streptococci), and m. catarrhalis. skin and soft-tissue infections caused by staphylococcus aureus (including ?-lactamase producing strains), s. pyogenes (group a beta-haemolytic streptococci) and staphylococcus epidermidis (including ?-lactamase produc

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate, quantity: 52.45 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: citric acid; colloidal anhydrous silica; xanthan gum; sucrose; sodium benzoate; allura red ac; sodium citrate dihydrate; flavour; potable water; simethicone; cetostearyl alcohol - infections due to susceptible microorganisms. lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis and tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate, quantity: 26.23 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: citric acid; xanthan gum; sucrose; sodium citrate dihydrate; colloidal anhydrous silica; sodium benzoate; allura red ac; flavour; potable water; simethicone; cetostearyl alcohol - infections due to susceptible microorganisms. lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis and tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 500 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes   lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae , haemophilus influenzae, and streptococcus pyogenes   pharyngitis and tonsillitis , caused by streptococcus pyogenes   note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphy